Genelabs Technologies, Inc.
Records under this name other than patents Genelabs Technologies, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Genelabs Technologies, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,064,218 | Novel Aromatic Compounds and Poly(OXYALKYLENE) Containing Aromatic Compounds Possessing Antibacterial, Antifungal or Antitumor Activity Formerly held Term ended Term ended Jan 18, 2024 · High confidence | Term ended | Term ended Jan 18, 2024 | High confidence |
| US 6,951,880 | Aryl and Heteroaryl Compounds as Antibacterial and Antifungal Agents Formerly held Term ended Term ended May 15, 2023 · High confidence | Term ended | Term ended May 15, 2023 | High confidence |
| US 7,144,486 | Multilayer Microcavity Devices and Methods Formerly held Term ended Term ended Jan 3, 2019 · Medium confidence | Term ended | Term ended Jan 3, 2019 | Medium confidence |
| US 6,107,023 | DNA amplification and subtraction techniques Formerly held Term ended Term ended Aug 22, 2017 · From the USPTO record | Term ended | Term ended Aug 22, 2017 | From the USPTO record |
| US 7,151,089 | Nucleoside Compounds for Treating Viral Infections Formerly held Lapsed on the fee record Ended Dec 19, 2014 · Medium confidence | Lapsed on the fee record | Ended Dec 19, 2014 | Medium confidence |
| US 7,144,868 | Nucleoside Compounds for Treating Viral Infections Formerly held Lapsed on the fee record Ended Dec 5, 2014 · Medium confidence | Lapsed on the fee record | Ended Dec 5, 2014 | Medium confidence |
| US 7,141,680 | Novel Aromatic Compounds Possessing Antifungal or Antibacterial Activity Formerly held Lapsed on the fee record Ended Nov 28, 2014 · High confidence | Lapsed on the fee record | Ended Nov 28, 2014 | High confidence |
| US 6,455,492 | Hepatitis E virus vaccine and method Lapsed on the fee record Ended Sep 24, 2014 · From the USPTO record | Lapsed on the fee record | Ended Sep 24, 2014 | From the USPTO record |
| US 7,094,768 | Nucleoside Derivatives for Treating Hepatitis C Virus Infection Formerly held Lapsed on the fee record Ended Aug 22, 2014 · High confidence | Lapsed on the fee record | Ended Aug 22, 2014 | High confidence |
| US 7,045,513 | DHEA composition and method Lapsed on the fee record Ended May 16, 2014 · From the USPTO record | Lapsed on the fee record | Ended May 16, 2014 | From the USPTO record |